Numerionlabs
numerionlabs.ai
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Atomwise is a San Francisco company founded in 2012 that pioneered the use of convolutional neural networks for structure-based small molecule discovery. Its screening system evaluates billions of virtual compounds against protein targets to shortlist candidates for synthesis and testing. The company runs internal programmes and collaborates with pharmaceutical partners and academic groups on difficult targets.
News
Numerion Labs Publishes Breakthrough AI Research on Ultra-Fast Screening of Hyper-Scalable Virtual Libraries with NVIDIA
APEX Protocol Enables Exhaustive Evaluation of 10 Billion Virtual Compounds in Under 30 Seconds San Francisco, CA - October 29, 2025 - Numerion Labs, an AI-native company pioneering the application of AI/ML to drug discovery, today announced the release o
Read more
Report
Atomwise, Hansoh Pharma Enter Into Up-to-$1.5B AI-Based Drug Discovery Partnership
Atomwise and Jiangsu Hansoh Pharmaceutical Group-the Chinese company behind this year's largest biopharma initial public offering (IPO)-said today they have launched an up-to-$1.5 billion collaboration to design and discover potential drug candidates for
Read more
Report
Atomwise and China's Hansoh announce potential $1.5bn AI drug discovery deal
Atomwise and Hansoh Pharma have announced an artificial intelligence (AI) drug discovery deal that could be worth $1.5 billion, the largest US-China collaboration in the field.
Read more
Report